In compliance with the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015, Biocon has informed about press release titled ‘Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee, Biosimilar Insulin Glargine’.
The above information is a part of company’s filings submitted to BSE.